JP6185932B2 - 免疫原性のｈｐｖのｌ２を含むｖｌｐ並びに関連する組成物及び方法 - Google Patents
免疫原性のｈｐｖのｌ２を含むｖｌｐ並びに関連する組成物及び方法 Download PDFInfo
- Publication number
- JP6185932B2 JP6185932B2 JP2014552287A JP2014552287A JP6185932B2 JP 6185932 B2 JP6185932 B2 JP 6185932B2 JP 2014552287 A JP2014552287 A JP 2014552287A JP 2014552287 A JP2014552287 A JP 2014552287A JP 6185932 B2 JP6185932 B2 JP 6185932B2
- Authority
- JP
- Japan
- Prior art keywords
- hpv
- peptide
- virus
- coat
- vlp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title description 22
- 230000002163 immunogen Effects 0.000 title description 21
- 238000000034 method Methods 0.000 title description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 125
- 241000701806 Human papillomavirus Species 0.000 claims description 101
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 72
- 229920001184 polypeptide Polymers 0.000 claims description 55
- 241001515965 unidentified phage Species 0.000 claims description 36
- 239000000539 dimer Substances 0.000 claims description 26
- 229960005486 vaccine Drugs 0.000 claims description 25
- 239000002245 particle Substances 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 101710132601 Capsid protein Proteins 0.000 description 36
- 101710094648 Coat protein Proteins 0.000 description 36
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 36
- 101710125418 Major capsid protein Proteins 0.000 description 36
- 101710141454 Nucleoprotein Proteins 0.000 description 36
- 101710083689 Probable capsid protein Proteins 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 24
- 241001112090 Pseudovirus Species 0.000 description 24
- 108091026890 Coding region Proteins 0.000 description 23
- 208000015181 infectious disease Diseases 0.000 description 22
- 238000013518 transcription Methods 0.000 description 15
- 230000035897 transcription Effects 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 101100049401 Human papillomavirus type 16 L2 gene Proteins 0.000 description 11
- 210000000234 capsid Anatomy 0.000 description 11
- 230000005847 immunogenicity Effects 0.000 description 11
- 230000003472 neutralizing effect Effects 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 208000009608 Papillomavirus Infections Diseases 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000709744 Enterobacterio phage MS2 Species 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 101710163801 Minor capsid protein L2 Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000709749 Pseudomonas phage PP7 Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 229960002566 papillomavirus vaccine Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 244000105975 Antidesma platyphyllum Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000009424 haa Nutrition 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000010845 search algorithm Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 206010051999 Anogenital dysplasia Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
- 101000742340 Human papillomavirus type 16 Minor capsid protein L2 Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 101710135729 Major capsid protein L1 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010031112 Oropharyngeal squamous cell carcinoma Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000022698 oropharynx squamous cell carcinoma Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000001307 recurrent respiratory papillomatosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18141—Use of virus, viral particle or viral elements as a vector
- C12N2795/18142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18141—Use of virus, viral particle or viral elements as a vector
- C12N2795/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261585839P | 2012-01-12 | 2012-01-12 | |
| US61/585,839 | 2012-01-12 | ||
| PCT/US2013/020960 WO2013106525A1 (en) | 2012-01-12 | 2013-01-10 | Immunogenic hpv l2-containing vlps and related compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504897A JP2015504897A (ja) | 2015-02-16 |
| JP2015504897A5 JP2015504897A5 (enExample) | 2016-03-03 |
| JP6185932B2 true JP6185932B2 (ja) | 2017-08-23 |
Family
ID=48781889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552287A Expired - Fee Related JP6185932B2 (ja) | 2012-01-12 | 2013-01-10 | 免疫原性のｈｐｖのｌ２を含むｖｌｐ並びに関連する組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2802349B1 (enExample) |
| JP (1) | JP6185932B2 (enExample) |
| CN (1) | CN104159606A (enExample) |
| AU (1) | AU2013207962B2 (enExample) |
| BR (1) | BR112014017242A8 (enExample) |
| CA (1) | CA2861021A1 (enExample) |
| HK (1) | HK1203837A1 (enExample) |
| WO (1) | WO2013106525A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549976B1 (en) | 2012-11-16 | 2017-01-24 | Stc.Unm | Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US9943580B2 (en) | 2013-09-12 | 2018-04-17 | Stc.Unm | Malaria vaccine |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US10821167B2 (en) | 2016-02-02 | 2020-11-03 | Unm Rainforest Innovations | VLP-based vaccines for targeting Staphylococcus aureus secreted virulence factors |
| US11371059B2 (en) | 2016-05-13 | 2022-06-28 | Flash Therapeutics | Viral particle for the transfer of RNAs, especially into cells involved in immune response |
| US11421011B2 (en) | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| CA3076631A1 (en) * | 2017-09-29 | 2019-04-04 | Deutsches Krebsforschungszentrum | Cutaneous papilloma virus vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9113809D0 (en) * | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
| GB9420146D0 (en) * | 1994-10-06 | 1994-11-23 | Cancer Res Campaign Tech | Papillomavirus vaccine |
| US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| AU2005281743A1 (en) * | 2004-08-04 | 2006-03-16 | Cytos Biotechnology Ag | Carrier conjugates of GnRH-peptides |
| WO2011100234A2 (en) * | 2010-02-09 | 2011-08-18 | Stc.Unm | Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods |
-
2013
- 2013-01-10 JP JP2014552287A patent/JP6185932B2/ja not_active Expired - Fee Related
- 2013-01-10 AU AU2013207962A patent/AU2013207962B2/en not_active Ceased
- 2013-01-10 CA CA2861021A patent/CA2861021A1/en not_active Abandoned
- 2013-01-10 CN CN201380012267.6A patent/CN104159606A/zh active Pending
- 2013-01-10 EP EP13736349.5A patent/EP2802349B1/en active Active
- 2013-01-10 HK HK15104584.7A patent/HK1203837A1/xx unknown
- 2013-01-10 WO PCT/US2013/020960 patent/WO2013106525A1/en not_active Ceased
- 2013-01-10 BR BR112014017242A patent/BR112014017242A8/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2802349A4 (en) | 2015-08-26 |
| JP2015504897A (ja) | 2015-02-16 |
| WO2013106525A1 (en) | 2013-07-18 |
| CA2861021A1 (en) | 2013-07-18 |
| EP2802349A1 (en) | 2014-11-19 |
| CN104159606A (zh) | 2014-11-19 |
| AU2013207962B2 (en) | 2017-07-20 |
| BR112014017242A8 (pt) | 2017-07-04 |
| AU2013207962A1 (en) | 2014-08-07 |
| BR112014017242A2 (pt) | 2017-06-13 |
| EP2802349B1 (en) | 2017-12-06 |
| HK1203837A1 (en) | 2015-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6185932B2 (ja) | 免疫原性のｈｐｖのｌ２を含むｖｌｐ並びに関連する組成物及び方法 | |
| Tumban et al. | A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2 | |
| HK1244695A1 (zh) | Hpv颗粒及其用途 | |
| Pineo et al. | Immunogenic assessment of plant‐produced human papillomavirus type 16 L1/L2 chimaeras | |
| US9884107B2 (en) | Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods | |
| CN101343315B (zh) | 截短的人乳头瘤病毒6型l1蛋白 | |
| Gersch et al. | New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention | |
| US20170096456A1 (en) | Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods | |
| Zhang et al. | A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types | |
| US9717783B2 (en) | Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods | |
| Villa | Vaccines against papillomavirus infections and disease | |
| Motavalli Khiavi et al. | A Dual‐Type L2 11‐88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross‐Reactive Antibodies in Vaccinated Mice | |
| WO2008082719A2 (en) | Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors | |
| CN101115766B (zh) | 用于抗人乳头瘤病毒型16的salmonella疫苗菌株的密码子经优化的hpv16l1 | |
| WO2016026401A1 (zh) | 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用 | |
| Wang et al. | Combined truncations at both N-and C-terminus of human papillomavirus type 58 L1 enhanced the yield of virus-like particles produced in a baculovirus system | |
| García-Carrancá | Vaccines against human papillomavirus and perspectives for the prevention and control of cervical cancer | |
| WO2004062584A2 (en) | Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection | |
| Shokri et al. | Designing of DNA vaccine based on a secretory form of major capsid protein of human papillomavirus type 18 | |
| RU2852174C1 (ru) | Рекомбинантная вакцина против вируса гриппа а человека и способ ее получения | |
| CN114874338B (zh) | 一种口蹄疫病毒纳米颗粒及其制备方法和应用 | |
| Tornesello et al. | Virus‑like particles as preventive and therapeutic cancer vac‑cines. Vaccines. 2022; 10: 227 | |
| JP6916115B2 (ja) | ＨＰＶＬ２ペプチド／ＨＢｓキメラタンパク質を有効成分とするＨＰＶ感染症用ワクチン | |
| Kazaks et al. | 11 Papillomavirus-Derived Virus-Like Particles | |
| Zhai | A broadly protective thermostable next generation HPV vaccine based on a concatemer peptide and a consensus peptide of L2 displayed on bacteriophage virus-like particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160112 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160112 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161114 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170414 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170515 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170516 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170711 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170728 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6185932 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |